Plain-English translation of NCT06405230 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial investigated two immunotherapy medications— and —for treating recurrent non-small cell lung cancer. The study was designed to test whether new biomarker tools (special lab tests using fluid samples, lab-grown tumor tissue, and special imaging scans) could predict how well these treatments would work for each patient.
Currently, doctors cannot easily predict which patients will respond well to immunotherapy before starting treatment. This trial was exploring whether new biomarker tools could help doctors choose the right treatment for each person and identify responders earlier, potentially improving outcomes for people with advanced lung cancer.
Participants would receive one of two medication regimens (either or , with or without standard chemotherapy). Throughout treatment, participants would undergo special tests including blood draws to check biomarkers, specialized imaging scans, and possibly multiple tumor biopsies. The trial was designed as a small pilot study to evaluate whether these new biomarker tools could predict treatment response, though the trial has since been terminated.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United Kingdom